Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease

Summary

This study evaluates the effect of ORM-12741 on agitation/aggression symptoms in Alzheimer's disease. Two thirds of the patients will receive ORM-12741 and one third will receive placebo.

Timeline

Start

2015-08-14

Primary completion

2017-10-09

Completion

2017-12-04

Outcome

Missed primary endpoint

release “clinical trial with an alpha-2c adrenoceptor antagonist (ORM-12741 for Alzheimer's disease) conducted in collaboration with Janssen Pharmaceuticals, Inc. as the trial did not meet the efficacy objectives” orionpharma.com ↗

Drugs

Indications